GlobeNewswire

ProMIS Neurosciences Issues Chairman’s Memorandum

Share

Notes and comments after the first AAIC meeting in the era of approved disease-modifying therapies for Alzheimer’s Disease

TORONTO and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued today a Chairman’s memorandum, commenting on highlights of the recent 2021 Alzheimer’s Association International Conference (AAIC) with relevance to ProMIS and summarizing the ProMIS poster/oral presentation contributions to the meeting.

“We are in a new era in the fight against Alzheimer’s, ALS, and other neurodegenerative diseases,” stated Eugene Williams, Executive Chairman of ProMIS Neurosciences. “ProMIS and many others have predicted this development and we believe that the Alzheimer’s community will look back on 2021 as a turning point, just as 2010 was a turning point in immuno-oncology and the fight against cancer. There were many signs of that recognition at the 2021 AAIC meeting.”

Alzheimer’s disease (AD)
The Chairman’s memorandum highlights the recent FDA accelerated approval of Biogen’s Aduhelm (aducanumab) which now provides a regulatory path to approval in AD, opening the door to development of next generation therapies selectively targeting the pathogenic forms of amyloid-beta.

To date, therapies such as Aduhelm, Eisai’s BAN2401 (lecanumab) and Lilly’s donanemab that target aggregated amyloid-beta (neurotoxic oligomers and plaque) have all shown clinical benefit in AD; therapies that target monomer or are non-selective, targeting all forms of amyloid-beta, have failed in every clinical trial. Clinical data suggest that oligomer targeting is actually the cause of benefit (not plaque).

ProMIS’ PMN310 is well positioned to be the best of the next generation therapies in Alzheimer’s, with extremely high selectivity for the toxic oligomer, effector function with the potential for efficacy at a low dose, and the possibility of both intravenous and subcutaneous delivery.

ProMIS presentations at AAIC.
ProMIS’ unique platform uses computational approaches to predict the particular shape (or conformation) of misfolded proteins, identifying conformational epitopes exposed only on neurotoxic misfolded proteins. In our poster presentation at AAIC (link to poster), we identified a novel scientific insight into disease pathogenesis, suggesting that in addition to selectively binding and neutralizing those neurotoxic proteins, ProMIS antibodies may slow the rate of propagation or spread of toxicity.

ProMIS’ technology platform has created a large and growing portfolio of highly selective, high affinity antibodies against multiple misfolded proteins involved in neurodegenerative disease, exemplified by our TDP-43 antibodies and intrabodies, presented by CSO Neil Cashman at AAIC (link to presentation). Intrabody data provide initial proof of concept for a gene therapy, vectorized antibody therapeutic, suggesting potential safety and efficacy for that approach in ALS.

To access the Chairman’s Update, please visit www.promisneurosciences.com or visit https://promisneurosciences.com/news/chairmans-update-august-4-2021/

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines – ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn.

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

CORRECTION: Huhtamaki completes the acquisition of Elif, a major supplier of sustainable flexible packaging to global brand owners23.9.2021 19:15:00 CEST | Press release

HUHTAMÄKI OYJ PRESS RELEASE 23.9.2021 AT 20:15 CORRECTION: Huhtamaki completes the acquisition of Elif, a major supplier of sustainable flexible packaging to global brand owners In Huhtamäki Oyj’s press release concerning the closure of the acquisition of Elif published on September 23, 2021 at 17:30 EET, the cash free debt free purchase price was incorrect. The incorrect sentence was: The cash free debt free purchase price was EUR 360 million (USD 422 million). The correct sentence is: The cash free debt free purchase price was EUR 412 million (USD 483 million). Below the corrected release in full: Further to the full approval of the Turkish competition authority Huhtamaki has completed the acquisition of Elif Holding A.Ş. (Elif), a major supplier of sustainable flexible packaging to global FMCG brand owners, with operations in Turkey and in Egypt. With this acquisition, Huhtamaki reinforces its position as a leading flexible packaging company in emerging markets and strengthens its e

SBM Offshore completes US$635 million bridge loan for FPSO Almirante Tamandaré23.9.2021 18:40:20 CEST | Press release

September 23, 2021 SBM Offshore is pleased to announce that it has secured a US$635 million bridge loan facility for the financing of the construction of FPSO Almirante Tamandaré. The facility was secured by the special purpose company which will own FPSO Almirante Tamandaré. Currently, SBM Offshore is the sole owner of this special purpose company. Discussions around the divestment of 45% of the equity ownership to partners continue to progress. The facility will be fully drawn in the coming days to finance the ongoing construction of the FPSO Almirante Tamandaré. The tenor of the bridge loan is twelve months with an extension option for another six months. Repayment is expected to take place upon closure and first drawdown of the project loan. CorporateProfile The Company’s main activities are the design, supply, installation, operation and the life extension of floating production solutions for the offshore energy industry over the full lifecycle. The Company is market leading in le

Beter Bed category winner best webshop of the year!23.9.2021 18:30:00 CEST | Press release

Sleep specialist Beter Bed was today voted category winner of the ‘ABN AMRO Webshop Award in the Netherlands’ for the fifth time. Beter Bed is now a nominee for the overall winner of the ‘ABN AMRO Best Retail Chain Award in the Netherlands’. The announcements were made during the category presentation ceremony for the ‘ABN AMRO Retailer of the Year the Netherlands’, at the ABN AMRO head office in Amsterdam. Beter Bed received the highest score from the consumer panel in the Web shop category, beating off competition from other webshops in the Sleeping category. John Kruijssen, CEO of Beter Bed Holding, is delighted and proud that Beter Bed was once again awarded the Webshop Award. “Within our omni-channel strategy the digital channel is becoming increasingly important, as is confirmed by our customers with this award. This title will be a real boost to the launch of our digital organisation under the name LUNEXT. LUNEXT, Beter Bed’s new employer brand, will serve as the vehicle for the

ORANGE BELGIUM LAUNCHES HEY! A NEW, 100% DIGITAL BRAND AIMED AT ULTRA-CONNECTED CUSTOMERS23.9.2021 18:10:00 CEST | Press release

Press release Brussels, September 23rd , 2021 With its new positioning Tomorrow is ours to make, Orange Belgium goes one step further in addressing all customer needs via the launch of a new and innovative b-brand to answer the needs of digital-savvy customers. hey! is a 100% digital brand which takes a participative approach specially designed to meet the needs of ultra-connected customers whose life is completely digitally oriented. This next generation value proposition is based on 4 pillars: 100% digital, Generous,Low impact, Evolutive. hey! will shake up the market by putting communities at the heart of its offers. The threehey! offers which boast attractiveonline pricing with extensive mobile data , will be launched on the 24th of September 2021. 100% digital hey! meets the needs generated by new internet usages, which have become increasingly popular, particularly among digitally active customers. hey! is aimed at those who love efficiency and getting things done in a few clicks

Medela’s Global Breastfeeding Symposium Convenes Community Focused on Establishing a Perpetual and Holistic Model to Advance Breastfeeding and Lactation Research23.9.2021 17:17:22 CEST | Press release

Call to Action for Researchers and Healthcare Professionals to Improve Infant Health Outcomes by Protecting and Promoting Breastfeeding Baar, Switzerland, Sept. 23, 2021 (GLOBE NEWSWIRE) -- *the English version shall prevail. Medela, a leading breast pump brand and medical device manufacturer, concluded its 15th Global Breastfeeding and Lactation Symposium with 1,400 people tuning in virtually from around the world. Medela convened a diverse group of global health leaders and lactation experts to share the latest research and insights in lactation and human milk, empowering the lactation and breastfeeding community with key information to support a strong call to action: respond to future pandemic threats with lactation needs in mind, improve clinical practice, better care for breastfeeding families and drive change. “There is power in bringing the top minds together to focus on improving infant and women’s health. Over the past two days, leading scientists from six countries shared th

Huhtamaki completes the acquisition of Elif, a major supplier of sustainable flexible packaging to global brand owners23.9.2021 16:30:00 CEST | Press release

HUHTAMÄKI OYJ PRESS RELEASE 23.9.2021 AT 17:30 Huhtamaki completes the acquisition of Elif, a major supplier of sustainable flexible packaging to global brand owners Further to the full approval of the Turkish competition authority Huhtamaki has completed the acquisition of Elif Holding A.Ş. (Elif), a major supplier of sustainable flexible packaging to global FMCG brand owners, with operations in Turkey and in Egypt. With this acquisition, Huhtamaki reinforces its position as a leading flexible packaging company in emerging markets and strengthens its existing flexible packaging business in attractive consumer product categories. The net sales of the acquired business were approximately EUR 163 million (USD 195 million) in 2020. Elif employs approximately 1,500 people in its two manufacturing locations in Istanbul, Turkey and Cairo, Egypt. The cash free debt free purchase price was EUR 360 million (USD 422 million). The acquired business will be reported as part of Huhtamaki´s Flexible